Prostate Cancer - Results from #160

Role of PSMA PET/CT in imaging and management of prostate cancer. March 13, 2025

Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial. March 13, 2025

Managing elderly patients with dual metastatic cancers-navigating diagnostic and treatment challenges. March 13, 2025

Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men. March 12, 2025

Cirrhosis and liver disease vs. adverse in-hospital outcomes after radical prostatectomy. March 12, 2025

An overview of utilizing artificial intelligence in localized prostate cancer imaging. March 12, 2025

Sexual Health Outcomes in Sexual Minority and Heterosexual Men After Prostate Radiation Therapy. March 12, 2025

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer. March 12, 2025

Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area Deprivation Index on Initial Treatment Type for Localized PCa in a North-American Cohort. March 12, 2025

Artera Announces 1st Patient Enrolled in PROSTATE-IQ Trial to Reduce Burden of Hormone Therapy in Men with Prostate Cancer Recurrence After Prostatectomy March 11, 2025

The Importance of Multi-parametric MRI, PET/CT, and Biopsy for Identifying and Delineating the Extent of Intraprostatic Radiorecurrent Prostate Cancer: A Secondary Analysis of the F-SHARP Clinical Trial. March 11, 2025

Comparative analysis of TARGET and PI-FAB scores in mpMRI surveillance after HIFU therapy for localized prostate cancer. March 11, 2025

Fatty acid binding protein 5 inhibitors as novel anticancer agents against metastatic castration-resistant prostate cancer. March 11, 2025

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study. March 11, 2025

Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England. March 11, 2025

Prostate Cancer: A Review. March 11, 2025

UK-based clinical testing programme for somatic and germline BRCA1/2, ATM and CDK12 mutations in prostate cancer: first results. March 10, 2025

Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC. March 10, 2025

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. March 10, 2025

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches. March 10, 2025

Page 9 of 1472